Development and evaluation of a novel TPGS-mediated paclitaxel-loaded PLGA-mPEG nanoparticle for the treatment of ovarian cancer

Chemical and Pharmaceutical Bulletin

Volumn 63, Issue 2, 2015, Pages 68-74

  Lv, Wen ^a   Cheng, Lihua ^b   Li, Baohua ^c  

^a Tongde Hospital of Zhejiang Province   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Nanoparticle; Ovarian cancer; Paclitaxel therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREMOPHOR; MACROGOL; PACLITAXEL; POLYGLACTIN; TOCOFERSOLAN; ANTINEOPLASTIC AGENT; DRUG CARRIER; MACROGOL DERIVATIVE; NANOPARTICLE; POLY(D,L-LACTIC-CO-GLYCOLIC ACID)-METHOXY-POLY(ETHYLENEGLYCOL) COPOLYMER;

ACUTE TOXICITY; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER THERAPY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LD 50; MOUSE; MULTIPLE CYCLE TREATMENT; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; OVARY CANCER; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; MALE; NUDE MOUSE; OVARIAN NEOPLASMS; PARTICLE SIZE; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MICE, NUDE; NANOPARTICLES; OVARIAN NEOPLASMS; PACLITAXEL; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; TRANSPLANTATION, HETEROLOGOUS;

EID: 84922388217     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.c14-00423     Document Type: Article

References (42)

1. Sehouli J., Oskay-Ozcelik G., Anticancer Res., 30, 4245-4250 (2010).
2. Marsh S., Int. J. Gynecol. Cancer, 19 (Suppl. 2), S30-S34 (2009).
3. Fransson M. N., Green H., Litton J. E., Friberg L. E., Drug Metab. Dispos., 39, 247-255 (2011).
4. Rowinsky E. K., Eisenhauer E. A., Chaudhry V., Arbuck S. G., Donehower R. C., Semin. Oncol., 20 (Suppl. 3), 1-15 (1993).
5. Kumar S., Mahdi H., Bryant C., Shah J. P., Garg G., Munkarah A., Int. J. Womens Health, 2, 411-427 (2010).
6. Zidan J., Hussein O., Abzah A., Tamam S., Farraj Z., Friedman E., Med. Oncol., 25, 274-278 (2008).
7. Matsumura Y., Kataoka K., Cancer Sci., 100, 572-579 (2009).
8. Matsumura Y., Jpn. J. Clin. Oncol., 38, 793-802 (2008).
9. Constantinides P. P., Lambert K. J., Tustian A. K., Schneider B., Lalji S., Ma W., Wentzel B., Kessler D., Worah D., Quay S. C., Pharm. Res., 17, 175-182 (2000).
10. Lundberg B. B., Risovic V., Ramaswamy M., Wasan K. M., J. Control. Release, 86, 93-100 (2003).
11. Li X., Li P., Zhang Y., Zhou Y., Chen X., Huang Y., Liu Y., Pharm. Res., 27, 1498-1511 (2010).
12. Kim S. C., Kim D. W., Shim Y. H., Bang J. S., Oh H. S., Kim S. W., Seo M. H., J. Control. Release, 72, 191-202 (2001).
13. Önyüksel H., Jeon E., Rubinstein I., Cancer Lett., 274, 327-330 (2009).
14. Sawant R. R., Sawant R. M., Torchilin V. P., Eur. J. Pharm. Biopharm., 70, 51-57 (2008).
15. Duncan R., Adv. Drug Deliv. Rev., 61, 1131-1148 (2009).
16. Nakamura J., Nakajima N., Matsumura K., Hyon S. H., Anticancer Res., 30, 903-909 (2010).
17. Hayashi Y., Skwarczynski M., Hamada Y., Sohma Y., Kimura T., Kiso Y., J. Med. Chem., 46, 3782-3784 (2003).
18. Agüeros M., Ruiz-Gaton L., Vauthier C., Bouchemal K., Espuelas S., Ponchel G., Irache J. M., Eur. J. Pharm. Sci., 38, 405-413 (2009).
19. Jackson J. K., Hung T., Letchford K., Burt H. M., Int. J. Pharm., 342, 6-17 (2007).
20. Venkatraman S. S., Jie P., Min F., Freddy B. Y., Leong-Huat G., Int. J. Pharm., 298, 219-232 (2005).
21. Hu X., Jing X., Expert Opin. Drug Deliv., 6, 1079-1090 (2009).
22. Song H., He R., Wang K., Ruan J., Bao C., Li N., Ji J., Cui D., Biomaterials, 31, 2302-2312 (2010).
23. Park J., Fong P. M., Lu J., Russell K. S., Booth C. J., Saltzman W. M., Fahmy T. M., Nanomedicine, 5, 410-418 (2009).
24. Chen H., Kim S., Li L., Wang S., Park K., Cheng J. X., Proc. Natl. Acad. Sci. U.S.A., 105, 6596-6601 (2008).
25. Huh K. M., Min H. S., Lee S. C., Lee H. J., Kim S., Park K., J. Control. Release, 126, 122-129 (2008).
26. Varma M. V., Panchagnula R., Eur. J. Pharm. Sci., 25, 445-453 (2005).
27. Neophytou C. M., Constantinou C., Papageorgis P., Constantinou A. I., Biochem. Pharmacol., 89, 31-42 (2014).
28. Zhao L., Feng S. S., J. Pharm. Sci., 99, 3552-3560 (2010).
29. Mu L., Seow P. H., Colloids Surf. B Biointerfaces, 47, 90-97 (2006).
30. Li P. Y., Lai P. S., Hung W. C., Syu W. J., Biomacromolecules, 11, 2576-2582 (2010).
31. Jin F., Tatavarti A., Int. J. Pharm., 389, 58-65 (2010).
32. Xie H., Smith J. W., J. Nanobiotechnology, 8, 18 (2010).
33. Chakravarthi S. S., De S., Miller D. W., Robinson D. H., Int. J. Pharm., 383, 37-44 (2010).
34. Suno M., Ono T., Iida S., Umetsu N., Ohtaki K., Yamada T., Awaya T., Satomi M., Tasaki Y., Shimizu K., Matsubara K., J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 860, 141-144 (2007).
35. Mittal A., Chitkara D., Kumar N., J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 855, 211-219 (2007).
36. Takei T., Kuge Y., Zhao S., Sato M., Strauss H. W., Blankenberg F. G., Tait J. F., Tamaki N., J. Nucl. Med., 46, 794-799 (2005).
37. Mainardes R. M., Evangelista R. C., Int. J. Pharm., 290, 137-144 (2005).
38. Elstad N. L., Fowers K. D., Adv. Drug Deliv. Rev., 61, 785-794 (2009).
39. Dong Y., Feng S. S., Biomaterials, 25, 2843-2849 (2004).
40. Bénard J., Da Silva J., De Blois M. C., Boyer P., Duvillard P., Chiric E., Riou G., Cancer Res., 45, 4970-4979 (1985).
41. Gao C., Pan J., Lu W., Zhang M., Zhou L., Tian J., Anticancer Drugs, 20, 807-814 (2009).
42. Bernabeu E., Helguera G., Legaspi M. J., Gonzalez L., Hocht C., Taira C., Chiappetta D. A., Colloids Surf. B Biointerfaces, 113, 43-50 (2014).